Primary gastrointestinal liposarcoma-a clinicopathological study of 8 cases of a rare entity.


Journal

Human pathology
ISSN: 1532-8392
Titre abrégé: Hum Pathol
Pays: United States
ID NLM: 9421547

Informations de publication

Date de publication:
03 2020
Historique:
received: 13 10 2019
revised: 15 12 2019
accepted: 17 12 2019
pubmed: 31 12 2019
medline: 27 10 2020
entrez: 30 12 2019
Statut: ppublish

Résumé

Primary gastrointestinal liposarcoma is rare, and information regarding this entity is largely based on single case studies. We report on 8 patients with primary liposarcoma of the gastrointestinal tract and review the pertinent literature. The cohort includes 6 men and 2 women who ranged in age from 51 to 81 years (median 68.5). Two tumors arose in the stomach, 4 in the small intestine, and 2 in the large intestine. Tumors ranged in size from 2.5 to 14.5 cm (median 7 cm), originated in the submucosa or muscularis propria of the intestinal wall, and frequently protruded into the bowel lumen, resulting in mucosal ulceration and luminal obstruction. Six tumors were dedifferentiated liposarcomas, and 2 were well-differentiated liposarcoma. Surgical excision was performed on all tumors except for 1 case of dedifferentiated liposarcoma. On follow-up, 1 patient with dedifferentiated liposarcoma developed a lytic sacral lesion suspicious for metastasis 4 months after resection of the primary, and another underwent marginal resection and presented with recurrence 4 years later, had tumor re-resection, and was considered disease-free at 6 weeks postsurgery. A third patient with dedifferentiated liposarcoma was alive with unknown disease status at 17 months following surgery, and another patient with dedifferentiated liposarcoma was alive without evidence of disease at 30 months following surgery. No follow-up information on the remaining patients is available. Overall, liposarcomas of the intestinal tract are most frequently high-grade dedifferentiated tumors that are biologically aggressive and require surgical excision with widely negative margins to help reduce the risk of local recurrence and dissemination. Important in the differential diagnosis is malignant gastrointestinal stromal tumor. Care must be taken not to misdiagnose one entity for the other because the correct diagnosis carries important therapeutic implications.

Identifiants

pubmed: 31884085
pii: S0046-8177(19)30233-3
doi: 10.1016/j.humpath.2019.12.004
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

80-93

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

David C Gajzer (DC)

Department of Pathology and Laboratory Medicine, University of Miami, Miami, FL.

Christopher D Fletcher (CD)

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Abbas Agaimy (A)

Institute of Pathology, University Hospital Erlangen, Germany.

Iva Brcic (I)

Institute of Pathology, Medical University of Graz, Austria.

Mahsa Khanlari (M)

Department of Pathology and Laboratory Medicine, University of Miami, Miami, FL.

Andrew E Rosenberg (AE)

Department of Pathology and Laboratory Medicine, University of Miami, Miami, FL. Electronic address: ARosenberg@med.miami.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH